Catheter Precision Receives Patents for Cardiac Electrophysiology Tech.

Catheter Precision, a medical device company, has received two new patents from the US Patent and Trademark Office. The first patent, "Methods of Ventricular Arrhythmia Localization Using a 3D Model," adds to the company's VIVO technology intellectual property portfolio and will be assigned to Kardionav, a joint venture between Catheter Precision and physicians. The second patent, "Neurostimulation Devices and Methods," focuses on improving cardiac ventricular function, especially in patients with heart failure, and will be assigned to Cardionomix, a majority-owned subsidiary of Catheter Precision.

Catheter Precision, Inc. (VTAK - NYSE/American), a leading U.S.-based medical device company, has received notification from the United States Patent and Trademark Office (USPTO) of the allowance for issuance of two new patents. The patents, which add to the company's intellectual property portfolio, are expected to enhance its offerings in the cardiac electrophysiology market.

The first patent, titled "Methods of Ventricular Arrhythmia Localization Using a 3D Model," will be assigned to Kardionav, a joint venture between Catheter Precision and physicians. This patent is a significant addition to the VIVO technology portfolio, which includes non-invasive 3D imaging systems for identifying the origin of ventricular arrhythmias pre-procedure. The VIVO system has received marketing clearance from the U.S. FDA and the CE Mark, indicating its regulatory approval and market readiness Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO^[1].

The second patent, titled "Neurostimulation Devices and Methods," will be assigned to Cardionomix, a majority-owned subsidiary of Catheter Precision. This patent focuses on improving cardiac ventricular function, particularly in patients with heart failure. Cardionomix, which holds several patents, aims to pursue heart failure therapy through stimulation of specific nerve endings found in the pulmonary arteries Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO^[1].

David Jenkins, CEO of Catheter Precision, commented, "We are pleased that additional intellectual property is being confirmed through the issuance of patents by the USPTO. This creates value for our different areas of technology and solidifies our beliefs that our products can be unique in a competitive medical device marketplace. We continue to have several applications on file and will continue to pursue new applications as part of our ongoing strategy."

These patents underscore Catheter Precision's commitment to innovation and its strategy to develop technologically advanced products for the cardiac electrophysiology market. The company's ability to secure these patents highlights its competitive edge and potential for growth in the medical device sector.